Home > Insider Trading > Filing (0000899243-20-008474)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Imara Inc.	IMRA	Pharmaceutical Preparations (2834)	811523849

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1700449	Plc Bioscience Arix	20 Berkeley Square Mayfair, London X0 W1J 6EQ		No	No	Yes	No
1756884	Ltd Holdings Bioscience Arix	20 Berkeley Square Mayfair, London X0 W1J 6EQ		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-16	1,367,058	$0.00	1,367,058	No	4	C	Indirect	By entities affiliated with Arix Bioscience plc
Common Stock	Acquisiton	2020-03-16	187,500	$16.00	1,554,558	No	4	P	Indirect	By entities affiliated with Arix Bioscience plc

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By entities affiliated with Arix Bioscience plc
No	4	P	Indirect	By entities affiliated with Arix Bioscience plc

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-03-16	8,611,110	$0.00	1,367,058	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.